Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
AGEN
AGEN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AGEN News
Agenus Triggers First $20M Payment in Zydus Collaboration
13h ago
seekingalpha
Agenus Triggers First Payment in Zydus Collaboration
13h ago
Newsfilter
Agenus to Release Q4 and Year-End 2025 Financial Results
6d ago
Businesswire
Agenus Announces Q4 and Year-End 2025 Financial Results Release
6d ago
Newsfilter
Agenus Unveils New Clinical Data on Botensilimab and Balstilimab
Feb 19 2026
Businesswire
Agenus' New Therapy Significantly Improves Survival Rates in Cancer Patients
Feb 19 2026
Newsfilter
Agenus Advances Immunotherapy with Botensilimab Data Presentation
Feb 09 2026
Newsfilter
Agenus Announces First Stakeholder Webcast of 2026 Focused on BOT+BAL Program
Jan 20 2026
Businesswire
Zydus Lifesciences Closes Acquisition of Agenus Assets, Establishes Zylidac Bio LLC
Jan 15 2026
PRnewswire
Zydus Lifesciences Closes Acquisition of Agenus Assets, Establishes Zylidac Bio LLC
Jan 15 2026
Newsfilter
Agenus Receives Approval for Updated AAC Protocol in France Expanding BOT+BAL Access
Jan 12 2026
Newsfilter
Agenus (AGEN) Q1 2025 Earnings Call Transcript
Jan 05 2026
NASDAQ.COM
Oncolytics Biotech Secures FDA Approval for First Pancreatic Cancer Immunotherapy
Dec 12 2025
Newsfilter
Agenus Names Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Medical Affairs and Early-Access Initiatives, Including France's AAC
Nov 18 2025
Newsfilter
Agenus Stock Jumps 8.67% Following Q3 Results and Clinical Achievements
Nov 10 2025
NASDAQ.COM
Agenus Announces Q3 2025 Results Highlighting Progress in Clinical and Regulatory Areas
Nov 10 2025
Newsfilter
Show More News
